Treatment with a drug
Retinal vascular occlusive disease - Treatment with a drug Factor
Last reviewed for CCPS 05 October 2006.
Investigative Documents
Claimant Report - Nonsteroidal Anti-Inflammatory Drugs (excluding Aspirin) [CR9266]
Medical Report - Treatment with NSAIDs (excluding Aspirin) [MR9345]
Preliminary questions [36282]
there is some evidence that a drug belonging to the nonsteroidal anti-inflammatory class of drugs, excluding aspirin, may be a factor in the development of the condition under consideration.36395 the veteran used a drug as specified in the reasonable hypothesis Statement of Principles before the clinical onset of the condition under consideration.
the veteran's use of a drug as specified in the reasonable hypothesis Statement of Principles was materially contributed to by treatment of an injury or illness which is identifiable.36751 — the veteran has established the causal connection between using a drug belonging to the nonsteroidal anti-inflammatory class of drugs, excluding aspirin, and VEA service for the clinical onset of retinal vascular occlusive disease.
36397 — the veteran has established the causal connection between using a drug belonging to the nonsteroidal anti-inflammatory class of drugs, excluding aspirin, and operational service for the clinical onset of retinal vascular occlusive disease.
or
36403 — the veteran has established the causal connection between treatment with a drug belonging to the selective cyclo-oxygenase 2 inhibitor class of drugs and eligible service for the clinical onset of retinal vascular occlusive disease.
Clinical onset and operational service [36397]
36399 — the identified illness or injury, for which the veteran used a drug belonging to the nonsteroidal anti-inflammatory class of drugs, excluding aspirin, is causally related to operational service.
Clinical onset and eligible service [36403]
for treatment of the identified illness or injury, the veteran was treated with a drug belonging to the selective cyclo-oxygenase 2 inhibitor class of drugs for a period specified in the balance of probabilities Statement of Principles before the clinical onset of the condition under consideration.36405 — the identified illness or injury, for which the veteran was treated with a drug belonging to the selective cyclo-oxygenase 2 inhibitor class of drugs, is causally related to eligible service.
Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/q-z/retinal-vascular-occlusive-disease-f059-h34/rulebase-retinal-vascular-occlusive-disease/treatment-drug